Skip to content

Biosimilars news

Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.

B.C.’s biosimilar initiative saves money, reinvests to expand drug coverage

Over the first five years of the initiative, the Province saved $732 million, thanks to people transitioning from reference biologics to their cost-effective biosimilars, which are highly similar versions of high-cost biologic drugs used to treat health concerns, such as diabetes, inflammatory conditions and certain cancers. 

Read more

New Canadian biosimilars resource

Health Canada has published a Handbook for health care professionals on biosimilar biologic drugs. 

Read more

Ontario achieves significant savings with oncology biosimilars

The use of oncology biosimilars has led to substantial annual savings in Ontario. In fiscal years 2020/21, 2021/22 and 2022/23, Ontario Health saved an estimated $53 million, $44 million, and $53 million, respectively.

Read more

Rate adjustments for people insured under the Public Prescription Drug Insurance Plan

The listing of generic and biosimilar medicines has largely helped to moderate the rise in rates, despite the increase in the number of insured individuals and the amount of drug consumption.

Read more

Biosimilars: cost reductions will not be automatic

Although the adoption rate for biosimilar medicine is increasing in Quebec and Canada, sponsors of private drug insurance plans will not necessarily benefit from the expected savings unless they are extremely vigilant.

Read more

New online courses support patients and health professionals managing biosimilar biologic medications

Read more
1 2 3 16